Drug Research
CureVac and Novartis Sign Initial Agreement on Manufacturing of COVID-19 Vaccine Candidate, CVnCoV
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), and Novartis AG announced that they have signed an initial agreement for the manufacturing of CureVac’s COVID-19 vaccine candidate, CVnCoV....
Drug Research
Clinerion and Medexprim join forces to combine clinical and imaging data for research
Clinerion and Medexprim have concluded a three-year partnership dedicated to the merger of electronic health records and imaging data into a private clinical data cloud warehouse dedicated to research.
Clinerion is the worldwide leader in medical data informatics, radically improving...
Drug Research
Stevanato Group launches AI platform to further enhance detection performance of its visual inspection machines
Stevanato Group, a leading global provider of integrated containment and delivery solutions to the biopharmaceutical and life sciences industries, has launched an Artificial Intelligence platform, based on Deep Learning (DL) models, that leverages the benefits of human-like decision-making in...
Drug Research
Merck and Transylvanian Institute of Neuroscience Cooperate on Brain-Inspired Artificial Intelligence
Merck, a leading science and technology company, announced a three-year collaboration with the Transylvanian Institute of Neuroscience (TINS), based in Cluj-Napoca, Romania. The primary focus of this collaboration between the private non-profit research institute TINS and the Artificial Intelligence...
Drug Research
Sanofi to provide manufacturing support to Johnson & Johnson for their COVID-19 vaccine to help address global supply demands
Sanofi has entered into an agreement with Janssen Pharmaceutical NV and Janssen Pharmaceuticals, Inc., two of the Janssen Pharmaceutical Companies of Johnson & Johnson, under which Sanofi will support manufacturing of Janssen´s COVID-19 vaccine in order to address the...
Drug Research
Lilly and Rigel collaborate to develop RIPK1 inhibitors for potential treatment of immunological and neurodegenerative diseases
Eli Lilly and Company and Rigel Pharmaceuticals, Inc. announced a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications including autoimmune and inflammatory diseases. Pursuant...
Drug Research
AstraZeneca, IDT To Ramp Up COVID-19 Vaccine Manufacturing In Europe
Following the European Medicines Agency (EMA) approval, millions of AstraZeneca vaccines began shipping on 5 February as part of the initial 17m doses that are due to be delivered over the next weeks, with more planned in March.
AstraZeneca and...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read